Estrella Immunopharma (ESLA) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Estrella Immunopharma is expected to report results before the market opens on May 13, with analysts forecasting ($0.0840) EPS; the company last reported ($0.01) EPS in March, beating prior estimates.
• Shares opened at $1.41 on Wednesday, down 8.1%, with a market cap of $60.02 million, a 52‑week range of $0.78–$3.15 and very low institutional ownership (~0.35%).
• Estrella is a preclinical T‑cell therapy developer (lead candidates EB103 and EB104) with a collaboration with Imugene on CF33‑CD19t; analyst coverage is mixed but the consensus rating is Hold with an $8 target.

Estrella Immunopharma (NASDAQ:ESLA - Get Free Report) is expected to announce its results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.0840) per share for the quarter.

Estrella Immunopharma (NASDAQ:ESLA - Get Free Report) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.17. On average, analysts expect Estrella Immunopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Estrella Immunopharma Stock Down 8.1%

Shares of ESLA stock opened at $1.41 on Wednesday. The company has a market cap of $60.02 million, a price-to-earnings ratio of -4.02 and a beta of 0.97. Estrella Immunopharma has a 52 week low of $0.78 and a 52 week high of $3.15. The firm has a 50 day moving average of $1.34 and a 200-day moving average of $1.55.

Institutional Trading of Estrella Immunopharma

Several hedge funds have recently bought and sold shares of ESLA. Geode Capital Management LLC grew its position in Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company's stock valued at $171,000 after purchasing an additional 8,318 shares during the period. Renaissance Technologies LLC grew its position in Estrella Immunopharma by 1,045.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company's stock valued at $191,000 after purchasing an additional 111,779 shares during the period. State Street Corp grew its position in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company's stock valued at $67,000 after purchasing an additional 20,900 shares during the period. Marshall Wace LLP acquired a new stake in Estrella Immunopharma in the 4th quarter valued at $88,000. Finally, Quadrature Capital Ltd acquired a new stake in Estrella Immunopharma in the 4th quarter valued at $43,000. Institutional investors and hedge funds own 0.35% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $8.00 price objective on shares of Estrella Immunopharma in a research report on Monday, February 9th. Weiss Ratings downgraded shares of Estrella Immunopharma from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Estrella Immunopharma from a "sell" rating to a "hold" rating in a research report on Saturday, January 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $8.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.